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a b s t r a c t
The effect of disease severity and dopaminergic medication on the assessment of familiarity and the
recollection of episodic details during recognition in nondementing idiopathic Parkinson’s is uncertain.
Some studies have reported familiarity as deﬁcient in mild Parkinson’s yet others have found it intact
even inmoderate Parkinson’s. Recollection has been found to be both preserved and deﬁcient inmild and
moderate Parkinson’s. The extent to which these conﬂicting ﬁndings are explained by disease severity
or dopaminergic medication or a combination of the two is uncertain, as all studies assessed patients in
a medicated state, and disease severity has not always been consistently reported.
Twelve patients with mild Parkinson’s and 11 with moderate Parkinson’s (medicated Hoehn and Yahr
mean: 2.1 and 3.2, respectively), completed matched versions of a yes/no recognition memory test
in a medicated and unmedicated condition (termed ON and OFF, respectively). Twenty-one matched
healthy volunteers also completed both memory tasks in 2 separate sessions (termed Blue and Green,
respectively).
In theON/Green condition, themoderate Parkinson’s recollectionperformancewas signiﬁcantly poorer
than the healthy volunteers and mild Parkinson’s. By contrast, recognition memory and familiarity
measures in both Parkinson’s group were relatively spared. In the OFF/Blue condition, the moderate
Parkinson’s recollection was impaired, but only in relation to the healthy volunteer set. There were
no signiﬁcant differences in recollection performance between the mild and moderate Parkinson’s
groups. Again, recognition memory and familiarity measures in both Parkinson’s group were relatively
spared. Further analyses showed the moderate patients’ recollection rates to be signiﬁcantly poorer
ON-medication compared to OFF.
These ﬁndings are discussed in relation to the staging of disease progression on medial temporal areas
which separately support recollection and familiarity, and the putative effects the different classes of
dopaminergic drugs may have on these areas.
© 2010 Published by Elsevier Ltd.
1. Introduction22
This study investigated the effect of dopaminergic medication23
and disease severity on the assessment of familiarity and the rec-24
ollection of episodic details during recognition in patients with25
nondementing idiopathic Parkinson’s. These processes differ with26
respect to the type of information that they provide and the level27
of recognition conﬁdence each typically produces. A widely held28
view holds that recollection is a high conﬁdence threshold process29
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that involves remembering speciﬁc details from episodic memory 30
regarding a past event. By contrast, recognition based on feelings of 31
familiarity varies continuously as a reﬂection of memory strength 32
in the absence of retrieval of contextual detail (Yonelinas & Jacoby, 33
1995). 34
There is conﬂicting evidence regarding the status of recollec- 35
tion and familiarity at different stages of Parkinson’s, with only 36
one study to date examining recollection in patients at different 37
stages of disease severity (Hay, Moscovitch, & Levine, 2002). In 38
this study, recollection was normal in the mild Parkinson’s group 39
(Hoehn & Yahr, 1967 rating severity ratings in the range of 1–2.5) 40
but signiﬁcantly declined in the moderate group (Hoehn and Yahr 41
[HY] 3–4). Familiarity was not assessed. Three other studies have 42
investigated the dual process view of recognition memory, sam- 43
pling patients at a single disease stage. It is important to note 44
that there was consistency between these studies in relation to 45
0028-3932/$ – see front matter © 2010 Published by Elsevier Ltd.
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their use of the remember–know paradigm and adoption of the46
formulae provided by Yonelinas and Jacoby (1995) to derive esti-47
mates of recollection and familiarity. Consistent with Hay et al.’s48
ﬁndings, recollection was spared in mild Parkinson’s (mean illness49
duration=5.79 years [HYnot provided], Davidson, Anaki, Saint-Cyr,50
Chow, & Moscovitch, 2006) and deﬁcient in moderate Parkin-51
son’s (HY 2–3, Edelstyn, Mayes, Condon, Tunnicliffe, & Ellis, 2007),52
although Barnes, Boubert, Harris, Lee, and David (2003) reported53
sparing of recollection in moderate Parkinson’s (mean HY 2.86)54
unless the patients had a history of visual hallucinations (mean HY55
3.39).56
The effect of disease severity on familiarity is also uncertain.57
In the study by Davidson et al. (2006), familiarity was impaired in58
mild Parkinson’s, whereas both Barnes et al. (2003) and Edelstyn59
et al. (2007) found it to be preserved in moderate Parkinson’s.60
We have identiﬁed four reasons (there may be others) why evi-61
dence is not fully concordant. First, although each of these studies62
assessed medicated patients, not all may have been in an optimally63
medicated state (e.g., Hay et al., 2002). Second, there is consider-64
able variation between studies in the mode of classifying disease65
stage. Third, neuropsychological characteristics of patients varied,66
with executive dysfunction present in some patients (Barnes et67
al., 2003; Edelstyn et al., 2007; Hay et al., 2002) but not others68
(Davidson et al., 2006). Fourth, a major problem of studies in this69
area is the accurate measurement of recollection and familiarity,70
and particularly of familiarity. This problem applies most strongly71
to the remember/know procedure where it is well established72
that procedural differences, inadequate training of participants73
and inadequate attempts to ensure participants understand the74
procedure, as may be the case when the remember–know pro-75
cedure is used in a surprise memory test (e.g., Barnes et al.,76
2003).77
An inﬂuential view in Parkinson’s research, is that deﬁcits in78
free recall (Daum et al., 1995; Gabrieli, Singh, Stebbins, & Goetz,79
1996; Ivory, Knight, Longmore, & Cardoc-Davies, 1999; Johnson,80
Pollard, Vernon, Tomes, & Jog, 2005) and recollection (Hay et81
al., 2002; Barnes et al., 2003) are contingent on a breakdown in82
prefrontally mediated memory processes underlying long-term83
memory encoding and retrieval strategies (such as the use of84
semantic organisation). Strategic memory processes are likely to85
depend, at least in part, on executive functions such as planning,86
decision-making and working memory (Shimamura, Janowsky, &87
Squire, 1991), which therefore places the origin of the recollection88
deﬁcits within the mesostriatal-frontal system. However, there is a89
growing body of evidence suggesting disruption of dopaminemod-90
ulation of mesolimbic structures, includes the ventral tegmental91
area and the hippocampus, may also contribute to recall and rec-92
ollection impairments in Parkinson’s. Evidence in support of this93
proposal is reviewed below.94
Firstly, animal studies demonstrate a critical role for dopamine95
in inducinghippocampal long-termpotentiation, a formof synaptic96
plasticity thought to underliememory storage (Lemon&Manahan-97
Vaughan, 2006; Mockett, Brooks, Tate, & Abraham; Otmakhova &98
Lisman, 1996; Wood et al., 2006), mediated by D1, D3, D4 and99
D5 dopamine receptors in the CA1–3 ﬁelds of the hippocampus100
(Bentivoglio & Morelli, 2005, chap. 1; Li, Cullen, Anwyl, & Rowan,101
2003;Mockett, Guévremont,Williams, &Abraham, 2007;O’Carroll,102
Martin, Sandin, Frenguelli, & Morris, 2006). Dopamine has also103
been shown to modulate synaptic plasticity in the perirhinal cor-104
tex (Bentivoglio & Morelli, 2005, chap. 1; Cummings et al., 2006;105
MacDonald, Cervenka, Farde, Nyberg, & Bäckman, 2009), mediated106
by D2 receptor (Bentivoglio & Morelli, 2005, chap. 1). It should be107
noted at this point, that involvement of the hippocampus in rec-108
ollection and the perirhinal cortex in familiarity has already been109
proposed in Aggleton and Brown’s (1999, 2006) still controversial110
dual process model of episodic memory.111
Secondly, anatomical evidence supporting a role of the 112
mesolimbic circuit in memory comes from a series of functional 113
magnetic imaging studies of healthy older adults. These investiga- 114
tions report a positive correlation between memory formation and 115
integrity/activation of the ventral tegmental area (Bunzeck et al., 116
2007; Düzel et al., 2008; Kumaran & Düzel, 2008; Wittman, Schiltz, 117
Boehler, & Düzel, 2008). Whilst it appears that reward-related acti- 118
vation of the medial substantia nigra pars compacta is associated 119
with improved hippocampus-dependent memory consolidation 120
(Wittman et al., 2005), encoding-related midbrain activation also 121
occurs independentlyof reward (Schott et al., 2004).Otherevidence 122
that genetic polymorphisms in the dopamine clearance pathways, 123
such as the dopamine transporter (DAT1), affect encoding-related 124
activation patterns in the midbrain and hippocampus (Schott et al., 125
2006) further supports the case that dopamine plays an important 126
role in memory. 127
Thirdly, Braak et al. (2003) (see also Braak & Del Tredici, 2008; 128
Braak, Rüb, & Del Tredici, 2006) examined the brains of 41 patients 129
obtained at autopsy by clinical severity and cognitive function 130
unknown at time of death. They proposed that-synuclein pathol- 131
ogy, the most abundant protein in Lewy bodies, spreads in a 132
predictable caudo-rostral direction through the brain, beginning in 133
the medulla oblongata and midbrain, before extending to the CA2 134
ﬁelds of the hippocampus and the transentorhinal region (i.e. the 135
medial portion of the perirhinal cortex, BA 35/35a, Garey, 1999; 136
Van Hoesen & Pandya, 1975; Taylor & Probst, 2008) and on to 137
the association and primary sensory areas and prefrontal cortex 138
(see Kalaitzakis, Graeber, Gentleman, & Pearce, 2008 for a criti- 139
cal discussion of this controversial model). According to Braak et 140
al.’s staging model, memory impairments are predicted based on 141
disruption of medial temporal lobe pathology, and furthermore, 142
hippocampal-dependent memory processes will decline prior to 143
perirhinal-dependent processes, due to relative sparing of lateral 144
perirhinal areas. However, the staging of these memory changes in 145
relation to clinical severity is unclear. 146
Magnetic resonance (MR) imaging studies of Parkinson’s 147
patients using manual volumetric and voxel-based morphometry 148
suggests recall impairments emerge, as early the mild–moderate 149
stages (mean HY 2.5, Ibarretxe-Bilbao et al., 2008) once hippocam- 150
pal pathology has reached a critical level (Brück, Kurki, Kaasinen, 151
Vahlberg, & Rinne, 2004; Camicoli et al., 2003; Camicioli, Moore, 152
Kerr, & Kaye, 1999; Duda et al., 2009; Laakso et al., 1996; but see 153
Burton, McKeith, Burn, Williams, & O’Brien, 2004; Bouchard et al., 154
2008; Beyer et al., 2009; Dashtipour et al., 2009; Jokinen et al., 155
2009). 156
In sum, the ﬁndings from animal research and MR studies of 157
healthy volunteers support a role for dopamine modulation of 158
hippocampal and perirhinal memory processes, and furthermore, 159
post-mortem studies of the brains of Parkinson’s patients and MR 160
studies of the hippocampus in nondementing Parkinson’s patients 161
indicate both structures are subject to the development of staged 162
pathology. 163
Dopaminergic medication, and here we are primarily consider- 164
ing l-dopa, can also have a signiﬁcant effect on cognitive function. 165
Evidence indicates that the requisite dopaminergic state neces- 166
sary to control motor symptoms has the potential to move the 167
same patient away from their optimum for certain cognitive func- 168
tions (see “l-dopa overdose hypothesis”, described by Gotham, 169
Brown, & Marsden, 1988; Cools, 2006; Cools, Barker, Sahakian, 170
& Robbins, 2001; Rowe et al., 2008), and may even lead to a 171
dopamine dysregulation syndrome, marked by an increase in risk- 172
takingbehaviour such as pathological gambling andhypersexuality 173
(Driver-Dunckley, Samanta, & Stacy, 2003; Dodd et al., 2005). The 174
relationship between the efﬁciency of neuronal activity and the 175
state of dopaminergic modulation in l-dopa overdose hypothesis 176
is represented by a Yerkes-Dodson inverted U-shaped curve with 177
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cognitive functions declining with deviation away from optimum178
dopamine levels, indicated by the centre of the curve. Extrapolating179
this model to recollection and familiarity, implies that l-dopa has180
the capacity to both improve and impair these kinds of memory181
depending on baseline dopamine levels in the underlying neural182
circuitry.183
The aim of our investigation was to investigate the impact of184
disease severity and dopaminergic medication on familiarity and185
recollection in nondementing idiopathic Parkinson’s. The predic-186
tions for our study have been informed by the application of the187
l-dopa overdose hypothesis (Cools, 2006) on dopamine-dependent188
medial temporal lobe memory circuits, the staging model of -189
synuclein pathology in Parkinson’s (Braak et al., 2003) and the190
neural correlates of the dual process view of recognition memory191
(Aggleton & Brown, 1999, 2006; Yonelinas et al., 2002). Our cen-Q3192
tral hypothesiswas that the neural pathways onwhich recollection193
and familiarity separately depend, are differentially affected by dis-194
ease progression, and consequently, the effects of dopaminergic195
medication on these memory measures will also differ.196
The method used in this study to assess the effects of l-dopa on197
recognitionmemory, familiarity and recollection is the controlled l-198
dopa withdrawal procedure. This requires patients to abstain from199
their dopaminergicmedication for a (“wash out”) period of 12–18h200
prior to the memory assessment. Performance in this OFF state is201
compared with performance on a separate testing session, taking202
place at the same timeof day as theOFF state, duringwhichpatients203
take their routine medication as usual. This procedure minimises,204
but does not eliminate, any effects that dopaminergic medication205
may have on recollection and familiarity. It is also less prone to the206
confounds of differences in disease severity compared to the alter-207
native of comparing de novo, i.e. never medicated, patients with208
the same individuals at a later stage after l-dopa administration, or209
a different already-treated group.210
Our ﬁrst set of predictions applied to patients tested in an211
unmedicated state. In mild Parkinson’s, we expected both recol-212
lection and familiarity to be preserved, contingent on the relative213
preservation of both the hippocampus, lateral and medial perirhi-214
nal cortical areas. By contrast, inmoderate Parkinson’s, a signiﬁcant215
decline in recollection was predicted, contingent on developing216
pathology in the hippocampus. By contrast, relative sparing of217
familiarity performance was expected, due to preservation of lat-218
eral (if not medial) areas of the perirhinal cortex.219
The second set of predictions pertained to the performance of220
the same patients assessed in a fully medicated state. We expected221
a l-dopa induced impairment of both recollection and familiar-222
ity in mild Parkinson’s, as routine medication overdosed (close223
to) optimal dopamine levels in the hippocampus and perirhi-224
nal cortex. By contrast, in moderate Parkinson’s, l-dopa should225
have a beneﬁcial effect on recollection, as medication remediated226
depleted dopamine levels in the hippocampus. Familiarity perfor-227
mance was again expected to show relative sparing, as the same228
l-dopa which ‘overdosed’ optimal dopamine levels in the lateral229
perirhinal cortex also restored depleted levels in medial perirhinal230
cortex.231
2. Participants232
Twenty-three Parkinson’s patients were recruited from the233
Parkinson’s disease outpatient clinic in the Department of Neurol-234
ogy, University Hospital of North Staffordshire. During a clinical235
interview (SJE), patients were screened for adverse clinical events236
or issues (e.g., drastic medication changes, fatigue, distress) that237
might affect performance.238
Medicated patients were subdivided into 2 subgroups based on239
HY score. Twelve patients rated as stage 1, 2 or 2.5 and classiﬁed240
as mild (mean HY=2.1, SD=0.42; mean illness duration=4.5 years, 241
SD=2.71), with a further 11were rated as stage 3 or 4 and classiﬁed 242
as moderate (mean HY=3.2, SD=0.41; mean illness duration=8.55 243
years, SD=2.84). 244
Details of the patients’ medication regimens are provided in 245
Table 1. There were no signiﬁcant differences in medication dose 246
between the mild and moderate Parkinson’s groups for the second 247
generation nonergoline dopamine agonists (t(22) =−1.52, p=0.15), 248
MAO-B inhibitors (t(22) =−1.45, p=0.16) or COMT inhibitors 249
(t(22) =−0.06, p=0.95). However, l-dopa dosewas signiﬁcantly dif- 250
ferent (t(22) =−2.08, p=0.05), with higher levels in the moderate 251
compared to the mild Parkinson’s group. 252
A single group of 21 healthy volunteers was recruited and 253
served as controls for both the mild and moderate Parkinson’s sub- 254
groups. The healthy volunteer set matched the mild Parkinson’s 255
subgroup for age (t(31) =0.7, p=0.49), premorbid IQ (t(31) =1.11, 256
p=0.28: National Adult Reading Test [NART], Nelson & Willison, 257
1991), current levels of functioning (t(31) =−1.5, p=0.13: Mini- 258
Mental State Examination [MMSE], Folstein, Folstein, & McHugh, 259
1975; t(31) =−0.56, p=0.58: The Cambridge Examination for Men- 260
tal Disorders of the Elderly [CAMCOG], Roth, Huppert, Mountjoy, & 261
Tym, 1998) and depression scores (t(31) =−1.7, p=0.11: Hamilton 262
Depression Inventory [HDI], Reynolds & Kobak, 1995). 263
The same healthy volunteer group also matched the mod- 264
erate Parkinson’s subgroup for age (t(30) =0.32, p=0.75), NART: 265
(t(31) =1.14, p=1.0); MMSE: (t(30) =−1.13, p=0.27); CAMCOG: 266
(t(30) =1.49, p=0.15) but not HDI: (t(30) =−3.11, p=0.004). 267
Comparison of motor symptoms ON- and OFF-medication 268
revealed a signiﬁcant improvement with medication for the 269
mild (t(31) =−2.5, p=0.03: Uniﬁed Parkinson’s Disease Rating Scale 270
[UPDRS], Fahn & Elton, 1987) and moderate Parkinson’s group 271
(UPDRS: t(30) =−3.35, p=0.007). 272
The demographic, clinical (patients only) and neuropsychologi- 273
cal characteristics of the participant groups are provided in Table 1. 274
Exclusion criteria for all participants included a MMSE score of 275
25 or less, presence of neurological or psychiatric history (apart 276
from Parkinson’s in the index group), history of substance abuse 277
(such as alcoholism), currently taking antidepressants, learning 278
difﬁculty (including dyslexia), or English as a second language. 279
Additional exclusion criteria for the patients were visual hallucina- 280
tions and/or delusions, dyskinesias or commenced dopaminergic 281
medication within the 2 months prior to the study. 282
3. Procedure 283
Two versions of a “yes/no” recognition memory test (RMT) 284
were constructed from a pool of 320 4–6 letter words (mean 285
word frequency=229.2 per million, range 83–1789; mean con- 286
creteness =462.7 and mean imageability =491.2) using the norms 287
provided by Coltheart (1981) and Baayen, Piepenbrock, and van 288
Rijn (1993). The pool comprised 160 high frequency words (word 289
frequency 229.2 per million, range 83–1789, concreteness =462.7, 290
imageability =491.2) and 160 low frequency words (mean word 291
frequency=1.9 per million, range 1–3, mean concreteness =472.1, 292
mean imageability =482.7). Both versions (termed RMT version 1 293
and RMT version 2) of the recognition memory tests were matched 294
for word frequency (RMT version 1: mean=115.4 per million, 295
range 1–1461, SD=160.51; RMT version 2: mean=115.65 per mil- 296
lion, range 1–1789, SD=160.87), concreteness (RMT version 1: 297
mean=467.9, SD=6.36; RMT version 2: mean=466.9, SD=8.79) 298
and imageability (RMT version 1: mean=487.2, SD=6.08; RMT 299
version 2: mean=486.5, SD=5.66), and for the size of relative rec- 300
ollection and familiarity contribution recorded at test. 301
At study, participants saw a mixture of 80 high frequency and 302
low frequency words for 3-s each (3-s inter-stimulus interval) and 303
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madea judgementas towhether thewordwaspleasant, unpleasant304
or neutral. Immediately after completing the study phase, recogni-305
tion using the yes/no procedure was tested by presenting each of306
the studied words (targets) randomly intermixed with 80 high fre-307
quency and low frequency new words or lures, that were matched308
to the targets for mean word frequency, concreteness and image-309
ability. Each word was presented individually, and recognition 310
judgements were made within a 3-s response window. 311
Correct identiﬁcation of a target itemwas deﬁned as a hit, whilst 312
false recognition of a lure was termed a false alarm. Following 313
each endorsement, irrespective of whether it was a hit or false 314
alarm, participants made a subjective judgement of their recogni- 315
Table 1
Demographic, neuropsychological and clinical (patients only) characteristics by group.
Group Gender Age MMSE NART HDI CAM HY Diag (years) UPDRS Medication—daily dose (mg)
ON OFF L-dopa Agonists MAO-B COMT
Parkinson’s disease patients (n=23)
PD 6 F 65 28 113 14.3 103 2 5 6 8 300 16 0 0
PD 7 M 75 30 124 1 104 2.5 3 5 13 250 9 0 0
PD 9 M 62 29 126 3.8 103 2.5 4 4 7 250 11 0 0
PD 10 M 59 30 126 4 100 2.5 2 11 11 100 11 0 0
PD 11 F 65 30 125 7.5 98 1 3 8 9 300 0 1 0
PD 12 M 71 30 127 4 98 2 6 10 10 200 7 1 0
PD 16 F 56 30 113 3.2 102 2 2 4 5 100 35 0 0
PD 18 M 64 30 124 11 100 2 4 8 10 100 56 10 0
PD 19 F 68 30 114 6 100 2 3 6 9 100 12 0 0
PD 20 M 63 29 109 8.5 99 2 4 6 6 250 0 0 0
PD 22 M 73 30 124 6.5 102 2.5 6 11 11 400 0 10 0
PD 24 M 71 30 115 3 101 2 12 7 7 300 16 0 0
PD 1 M 75 30 106 7.5 92 3 9 6 11 1000 4 0 0
PD 2 M 58 30 124 10.3 103 3 8 16 20 1200 12 10 0
PD 3 M 77 29 117 9.8 98 3 7 16 15 500 16 0 0
PD 4 M 64 30 98 18.2 101 4 10 20 23 375 24 0 200
PD 5 M 72 28 87 5.2 86 3 10 12 21 800 12 0 0
PD 8 M 64 29 109 3 99 3 6 15 17 250 16 1 0
PD 13 M 53 30 117 8.8 97 3 5 13 15 450 3 0 0
PD 14 M 69 30 123 10.7 100 3 14 14 17 525 16 5 0
PD 15 F 79 29 107 8.4 98 3 8 16 17 412.5 0 0 200
PD 17 F 76 30 123 7 100 4 12 17 17 1000 0 10 0
PD 23 M 55 30 118 4 100 3 5 7 7 450 12 0 0
Mean 17M/7F 66.7 29.57 115.7 7.2 99.3 2.61 6.43 10.3 12.43 417.93 12.52 2.09 17.39
SD 7.48 0.73 10.18 4.04 3.87 0.69 2.84 4.75 5.16 306.3 12.76 3.86 57.62
Mild PD subgroup (n=12)
Mean 8M/4F 66 29.67 120 6.07 100.8 2.08 4.5 7.17 8.83 220.83 14.42 1.83 0
SD 5.75 0.65 6.56 3.78 1.99 0.42 2.71 2.48 2.33 101.04 16.22 3.83 0
Moderate PD subgroup (n=11)
Mean 9M/2F 67.5 29.5 111.7 8.45 97.64 3.18 8.55 13.8 16.36 632.95 10.46 2.36 36.36
SD 9.25 0.81 11.67 4.11 4.76 0.41 2.84 4.19 4.48 312.56 7.741 4.06 80.9
Healthy volunteers (n=21)
HV 1 F 59 29 119 3 102
HV 2 F 64 28 113 3.5 100
HV 3 F 60 30 121 2.7 102
HV 4 M 66 30 119 2.2 102
HV 5 M 64 29 109 3 101
HV 6 M 72 30 121 0.7 99
HV 7 M 79 29 118 4 103
HV 8 F 64 30 124 11.4 102
HV 9 M 79 30 120 3.4 100
HV 10 F 50 28 116 1 99
HV 11 M 73 29 122 6.4 103
HV 12 F 77 26 110 5 90
HV 13 M 79 28 106 5.9 92
HV 14 M 67 30 118 4.2 102
HV 15 F 71 30 119 7 103
HV 16 M 77 30 124 3 104
HV 17 M 60 30 122 2 104
HV 18 M 72 29 101 9 101
HV 19 M 68 30 110 1 98
HV 20 M 54 29 107 4.4 99
HV 21 M 69 28 102 7 100
Mean 14M/7F 67.8 29.14 115.3 4.28 100.3
SD 8.29 1.062 7.149 2.79 3.538
Notes: Mild Parkinson’s (PD) subgroup consists of the following patients: PD 6, 7, 9–12, 16, 18–20, 22, 24; moderate PD subgroup: PD 1–5, 8, 13–15, 17, 23. SD, 1standard
deviation; MMSE, Mini-Mental State examination; NART, National Adult Reading Test; HDI, Hamilton Depression Inventory; CAM, The Cambridge Examination for Mental
Disorders of the Elderly—Revised; HY, Hoehn and Yahr; Diag, years since diagnosis; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale; ON, medicated state; OFF, unmedicated
state; agonists: ropinirole, pramipexole and rotigotine; COMT, catechol-O-methyl transferase inhibitors: tolcaponeandentacapone;MAO-B,monoamineoxidase-B inhibitors:
selegiline and rasagiline.
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Table 2
Mean hit and false alarm rates for recognition memory, know and remember rates in ON/Green and OFF/Blue conditions by group.
Group Recognition memory Know Remember
ON/Green OFF/Blue ON/Green OFF/Blue ON/Green OFF/Blue
HR FAR HR FAR HR FAR HR FAR HR FAR HR FAR
Parkinson’s disease patients (n=23)
Mean 58.5 7.17 57.17 5.83 20.58 5.46 17.78 4.39 37.92 1.71 39.39 1.44
SD 28.96 7.86 22.12 5.95 10.9 5.01 6.49 3.95 18.06 2.85 15.63 2.0
Mild PD subgroup (n=12)
Mean 63.39 6.47 61.23 6.15 17 4.85 15.92 3.92 46.39 1.62 45.31 2.23
SD 22.02 6.92 22.15 5.99 7.21 4.56 6.24 3.64 14.81 2.36 15.91 2.35
Moderate PD subgroup (n=11)
Mean 50.1 7.7 51.9 5.4 26.2 5.9 20.2 5.0 23.9 1.8 31.7 0.4
SD 23.96 9.52 18.25 4.97 13.06 5.86 6.29 4.45 10.9 3.66 11.96 0.52
Healthy volunteers (n=21)
Mean 67.38 10.5 67 8.52 15.95 7.24 15.19 6.81 51.43 3.29 51.81 1.71
SD 19.26 11.9 22.79 8.19 6.76 7.3 8.36 6.77 12.5 4.56 14.43 1.42
Notes: HR, hit rate; FAR, false alarm rate; SD, 1standard deviation.
tionexperience in termsof either feelings of familiaritywithout any316
recollection (‘know’ response) or a speciﬁc recollection of the item317
having been previously presented (‘remember’ response). The sec-318
ond stage was not time constrained. Participants were familiarized319
with the experimental set-up prior to completing both versions320
of the recognition memory task, and regular checks were made321
throughout the test phase to ensure that participants maintained a322
full understanding of the criteria for making a remember or know 323
decision. The guidance for the remember–know decision is available 324
on request from the lead author. 325
To examine the effect of dopaminergic medication on memory, 326
patients were tested in a fully medicated and unmedicated state 327
(termed ON and OFF, respectively). The healthy volunteers were 328
also tested for 2 sessions, labelled “Blue” and “Green”. This label 329
Table 3
Discrimination accuracy rates for recognition memory, familiarity and recollection rates in ON/Green and OFF/Blue conditions by group.
Group HY RM Familiarity Recollection Group RM Familiarity Recollection
ON OFF ON OFF ON OFF Green Blue Green Blue Green Blue
PD 6 2 3.1864 3.085 2.131 2.295 0.79 0.79 HV 2 1.985 1.914 1.28 1.364 0.593 0.469
PD 7 2.5 3.118 3.577 2.209 2.66 0.778 0.84 HV 9 0.797 0.973 0.528 0.435 0.247 0.272
PD 9 2.5 2.1827 2.282 1.707 1.874 0.395 0.407 HV 10 2.118 3.085 0.775 2.203 0.667 0.901
PD 10 2.5 2.7874 2.787 2.263 1.843 0.494 0.654 HV 11 2.51 2.32 1.678 1.145 0.753 0.802
PD 11 1 3.6908 3.41 2.464 2.682 0.778 0.679 HV 1 3.246 3.288 2.345 1.993 0.642 0.691
PD 12 2 1.0152 1.678 0.775 1.4 0.235 0.333 HV 3 4.095 3.679 2.968 2.732 0.84 0.802
PD 16 2 0.9541 1.838 0.62 1.463 0.259 0.444 HV 4 3.954 4.095 3.214 3.285 0.802 0.765
PD 18 2 2.1106 2.156 1.622 1.599 0.469 0.457 HV 5 2.612 2.411 2.189 1.88 0.494 0.531
PD 19 2 2.7327 1.815 2.13 1.592 0.605 0.691 HV 6 2.983 2.096 2.756 1.276 0.691 0.642
PD 20 2 2.8167 2.209 1.959 1.842 0.469 0.247 HV 7 1.847 2.843 1.346 2.467 0.543 0.63
PD 22 2.5 2.4661 1.532 1.687 0.894 0.593 0.531 HV 12 0.693 1.059 0.646 0.679 0.222 0.37
PD 24 2 2.3773 1.952 1.251 1.196 0.753 0.568 HV 8 4.587 3.274 2.964 2.632 0.877 0.84
PD 1 3 2.0619 2.156 1.678 1.322 0.296 0.543 HV 13 0.74 1.303 0.635 1.008 0.185 0.272
PD 2 3 1.6216 1.64 0.957 1.24 0.309 0.321 HV 14 2.377 2.657 1.757 1.863 0.642 0.728
PD 3 3 1.4658 1.176 1.139 0.791 0.296 0.296 HV 15 2.09 2.277 1.129 1.183 0.691 0.605
PD 4 4 1.4723 1.715 1.62 1.099 0.235 0.346
PD 5 3 2.2319 2.304 2.244 2.092 0.136 0.173 HV 16 3.213 3.274 2.113 2.292 0.741 0.79
PD 8 3 1.232 1.492 0.838 0.976 0.235 0.284 HV 17 1.939 1.538 1.412 1.162 0.358 0.395
PD 13 3 2.0543 1.684 1.462 1.333 0.21 0.259 HV 18 2.207 2.32 1.626 1.768 0.593 0.642
PD 14 3 2.1184 2.495 1.617 1.85 0.333 0.481 HV 19 2.697 2.343 1.923 1.557 0.63 0.63
PD 15 3 1.4179 1.575 1.308 1.026 0.185 0.272 HV 20 1.712 1.952 1.066 1.248 0.568 0.543
PD 17 4 1.9328 2.587 1.883 1.937 0.494 0.543
PD 23 3 2.2067 2.272 1.57 1.521 0.568 0.617 HV 21 3.118 3.085 2.37 2.561 0.704 0.667
Mean 2.61 2.1486 2.141 1.614 1.588 0.431 0.469 Mean 2.453 2.466 1.749 1.749 0.594 0.618
SD 0.69 0.6219 0.711 0.515 0.523 0.209 0.186 SD 1.049 0.845 0.821 0.741 0.196 0.181
Mild PD subgroup (n=12)
Mean 2.08 2.360 2.453 1.735 1.778 0.551 0.553
SD 0.42 0.691 0.817 0.589 0.548 0.198 0.183
Moderate PD subgroup (n=11)
Mean 3.182 1.918 1.801 1.483 1.381 0.3a,b ,c 0.376a
SD 0.405 0.462 0.364 0.408 0.424 0.129 0.145
Notes:Mild PD subgroup: PD 6, 7, 9–12, 16, 18–20, 22, 24;moderate PD subgroup: PD 1–5, 8, 13–15, 17, 23. SD, 1standard deviation; d′ , signal detection index of discrimination
accuracy;HR− FAR, hit rateminus false alarmrateproviding a thresholdmeasureof discriminationaccuracy;HY,HoehnandYahrdisease severity rating scale; RM, recognition
memory; ON, medicated state; OFF, unmedicated state.
a Signiﬁcantly impaired recollection rates compared to healthy volunteers.
b Signiﬁcantly impaired recollection rates compared to mild Parkinson’s at p<0.05.
c Signiﬁcantly impaired recollection rates compared to unmedicated moderate Parkinson’s at p=0.005.
Please cite this article in press as: Edelstyn, N. M. J., et al. Effect of disease severity and dopaminergic medication on recollection and familiarity
in patients with idiopathic nondementing Parkinson’s. Neuropsychologia (2010), doi:10.1016/j.neuropsychologia.2009.12.039
ARTICLE IN PRESS
UN
CO
RR
EC
TE
D 
PR
OO
F
GModel
NSY35391–9
6 N.M.J. Edelstyn et al. / Neuropsychologia xxx (2010) xxx–xxx
emphasized that there isnodifference in “treatment”between the2330
sessions: the “Blue”was yoked to theOFF session of the PDpatients,331
the “Green” to the ON session.332
In the ON condition, patients were tested in the morning, 2h333
after taking their ﬁrst medication of the day. To produce the OFF334
state, patientswereassessedat the same timeofdayhavingdelayed335
their ﬁrst morning medication. The time since last medication was336
12–14h. The order of RMT versions 1 and 2 were counterbal-337
anced across the ON/Green and OFF/Blue sessions, and the order of338
the ON/Green and OFF/Blue sessions were counterbalanced across339
participants. The study was approved by South Staffordshire NHS340
Research Ethics Committee.341
4. Results342
Recognition memory, know and remember false alarm and hit343
rates for the Parkinson’s and healthy volunteer groups are pre-344
sented in Table 2. A trend for higher false alarms by patients in345
the medicated compared to the unmedicated condition is evident346
but not signiﬁcant (t(22) =−0.42, p=0.68).347
A correction has been made to the data to eliminate extreme348
scores in accordance with Snodgrass and Corwin’s (1988) rec-349
ommendation. It is assumed that recollection and familiarity are350
stochastically independent at retrieval, and therefore, Yonelinas351
and Jacoby’s (1995) independence formula has been applied352
to the corrected know scores (familiarity = know/[1− remember]).353
Estimates of overall recognition and familiarity discrimination354
accuracy were calculated using signal detection theory (d′), and a355
threshold measure of recollection is reported (hit rate minus false356
alarm rate).357
Overall recognition, familiarity and recollection rates recorded358
during ON/Green and OFF/Blue sessions for the mild and moderate359
Parkinson’s groups and healthy volunteers are presented in Table 3360
and Fig. 1.361
The data was ﬁrst analyzed using a mixed 3 by 2 Multivari-362
ate Analysis of Covariance, with Group (healthy volunteers vs. mild363
Parkinson’s vs. moderate Parkinson’s) as the between-subjects fac-364
tor, and Condition (ON/Green vs. OFF/Blue) the within subjects365
factor. Depression was the covariate and the dependent variables366
were the measures of recognition memory, familiarity and recol-367
lection.368
There was a main effect of Group (F(2,40) =1.78, p=0.035),369
but not for Condition (F(2,40) =1.08, p=0.39), and the interaction370
failed to reach signiﬁcance (F(2,40) =1.33, p=0.25, respec-371
tively). The between-subjects tests revealed a signiﬁcant effect372
of Group on recollection (ON/Green: F(2,40) =7.47, p=0.002;373
OFF/Blue: F(2, 40) =4.81, p=0.013, respectively) but not on374
either recognition memory or familiarity (ON/Green recognition375
memory: F(2,40) =2.16, p=0.13; OFF/Blue recognition mem-376
ory: F(2,40) =1.14, p=0.33; ON/Green familiarity: F(2,40) =0.06,377
p=0.56; OFF/Blue familiarity: F(2,40) =0.093, p=0.4, respectively).378
Two one-way ANOVAs and Bonferroni post hoc tests investi-379
gated the locus of these effects further. In the ON/Green condition,380
there was no signiﬁcant difference between the healthy volunteers381
Fig. 1. Discrimination accuracy rates for recognition memory, familiarity (upper)
and recollection (lower) inON/Green andOFF/Blue conditions by group.Notes: Error
bars represent standard errors of the mean.
and patients with mild Parkinson’s, but both groups differed sig- 382
niﬁcantly from the moderate Parkinson’s group (ps <0.05). In the 383
OFF/Blue condition there was no difference between the mild and 384
moderate Parkinson’s patients or between themild Parkinson’s and 385
healthy volunteers, but the moderate Parkinson’s patients differed 386
signiﬁcantly from the healthy volunteers (p<0.05). 387
The next set of analyses consisted of a series of within group 388
paired t-tests examining the effect of medication on each of the 389
3 memory measures. In mild Parkinson’s, medication had no 390
effect on any of the memory measures (recognition memory: 391
t(11) =0.56, p=0.59; familiarity: t(11) =−0.32, p=0.76; recollec- 392
tion: t(11) =−0.06, p=0.96). There was also no effect of medication 393
on either recognition memory or familiarity in the moder- 394
ate Parkinson’s group (t(10) =−1.35, p=0.21; t(10) =1.3, p=0.22, 395
respectively). However, recollection rateswere signiﬁcantly poorer 396
ON-medication compared to OFF (t(10) =−3.58, p=0.005). Finally, 397
the healthy volunteers showed no effect of condition (Green/Blue) 398
on recognition memory, familiarity or recollection (t(20) =−0.11, 399
p=0.92; t(20) =−0.01, p=1.0; t(20) =−1.36, p=0.19, respectively). 400
Finally, z-scores were used to further explore the effect of dis- 401
ease severity on familiarity and recognition memory (see Table 4). 402
Although a deﬁcit in familiarity was not predicted, a subtle decline 403
in this measure is consistent with the development of pathology in 404
Table 4
z-scores for recognition memory, familiarity and recollection rates in ON and OFF conditions by mild and moderate Parkinson’s patients.
Group ON-medication OFF-medication
RM Familiarity Recollection RM Familiarity Recollection
Mild PD subgroup (n=12)
z-score −0.02 −0.03 −0.19 −0.18 −0.04 −0.48
Moderate PD subgroup (n=11)
z-score −0.45 −0.26 −1.1 −0.44 −0.35 −0.98
Notes: z-scores are based on the healthy volunteer performance; RM, recognition memory.
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medial perirhinal cortex with relative sparing of lateral perirhinal405
areas.406
Consistent with expectations, z-scores for recognition memory407
and familiarity, show a subtle decline with disease severity. Fur-408
thermore, the relatively more pronounced decline in recollection409
compared to the other memory measures adds further evidence in410
support of the claim for a relatively greater involvement of recol-411
lection impairment in Parkinson’s.412
5. Discussion413
Our study was designed to investigate the impact of disease414
severity and dopaminergic medication on the assessment of famil-415
iarity and the recollection of episodic details during recognition416
in patients with idiopathic, nondementing Parkinson’s. Our pre-417
dictions were derived from the convergence of three theories: the418
staging of-synuclein pathology in Parkinson’s (Braak et al., 2003);419
a dual process view of recognition memory (Aggleton & Brown,Q4420
1999, 2006; Yonelinas, 1994; see Yonelinas et al., 2002 for review);421
the l-dopa overdose hypothesis (Cools, 2006) and MR studies of422
hippocampal atrophy in patients at different stages of Parkinson’s.423
Our central hypothesis was that the neural circuits on which recol-424
lection and familiarity depend are differentially affected by disease425
progression, and consequently, the effects of dopaminergic medi-426
cation on familiarity and recollection will also differ.427
Our ﬁrst set of predictions, which applied to patients tested428
in an unmedicated state, were supported. The mild Parkinson’s429
group displayed the expected sparing of both recollection and430
familiarity, whereas the dissociation between deﬁcient recollec-431
tion and (relatively spared) familiarity emerged in the moderate432
Parkinson’s set. The second set of predictions, in contrast, were433
not supported. L-dopa neither remediated deﬁcient recollection in434
moderate Parkinson’s, nor did it impair the relatively preserved435
familiarity and recollection in mild Parkinson’s. In fact, dopamin-436
ergic medication had the opposite effect to that predicted, with437
recollection rates showingagreaterdecline inmedicatedcompared438
to unmedicated conditions.439
It could be suggested that the failure of the l-dopa overdose440
hypothesis to accurately predict the pattern of recollection and441
familiarity in our cohort of patients may be due to the fact that we442
have recruited an unrepresentative sample, an argument used pre-443
viously in relation to the recollection/familiarity proﬁle reported444
by Barnes et al. (2003) and Davidson et al. (2006). However, we445
would argue against this suggestion on the grounds that the proﬁle446
of our current empirical ﬁndings replicate two earlier dual pro-447
cess investigations of recognition memory in medicated patients448
(Edelstyn et al., 2007; Hay et al., 2002). So, for example, Hay et449
al. reported a signiﬁcant decline in recollection from normal lev-450
els in mild Parkinson’s to deﬁcient levels in moderate Parkinson’s;451
and Edelstyn et al. demonstrated a dissociation between signif-452
icantly impaired recollection and spared familiarity in moderate453
Parkinson’s patients compared to healthy controls.454
There is also the possibility that the absence of an l-dopa over-455
dose effect on relatively spared recollection inmild Parkinson’s and456
familiarity in mild and moderate, predicted by the Yerkes-Dodson457
inverted U-shaped curve, was due to low levels of l-dopa in our458
patients. However, the fact that an l-dopa overdose effect on famil-459
iarity was also absent from the moderate Parkinson’s group who460
were on a signiﬁcant higher l-dopa dose argues against this pro-461
posal.462
In addition to l-dopa, all butoneof ourpatientswereonadjuvant463
dopaminergic medication that included MAO-B inhibitors (selegi-464
line or rasagiline), COMT inhibitors (tolcapone or entacapone)465
and second generation nonergoline dopamine agonists (ropini-466
role hydrochloride, pramipexole hydrochloride or rotigotine). It is467
possible therefore, that the further decline of recollection in our 468
medicatedmoderateParkinson’s group,maystemfromwithdrawal 469
from one of these alternative dopamine enhancers in addition to l- 470
dopa. Studies examining the action of these classes of medication 471
on episodic memory are limited, but the consensus from animal 472
studies suggests thatneitherMAO-B inhibitorsnorCOMT inhibitors 473
are likely tobecontributory factors. Selegiline, for example, appears 474
to protect rather than impair spatial memory in rats (e.g., Martins 475
de Lima et al., 2005). Similar ﬁndings have also been noted for 476
tolcapone (e.g., Liljequist, Haapalinna, Ahlander, Li, & Mannisto, 477
1997). 478
A small number of studies have examined the effects of second 479
generation nonergoline dopamine agonists on cognitive function. 480
The focus has primarily been on pramipexole, where the dopamine 481
agonist has been shown to both improve performance on work- 482
ing memory and task switching tasks but impair certain forms 483
of probabilistic reversal learning (Cools, Altamirano, & D’Esposito, 484
2006; Cools et al., 2001; Costa, Peppe, Dell’Agnello, Caltagirone, & 485
Carlesimo, 2009). Pramipexole has also been linked with the devel- 486
opment of pathological gambling in a subset of Parkinson’s patients 487
(Driver-Dunckley et al., 2003; Dodd et al., 2005). Although nei- 488
ther our patients, nor their carers, reported any overt risk-taking 489
behaviour since commencing pharmacotherapy, it is possible that 490
their behaviour on the recognition memory tests may have been 491
affected, for example, by the adoption of a more liberal mode of 492
responding. Although false alarm rates were not signiﬁcantly ele- 493
vated in the ON condition, there was a trend for higher rates in the 494
ON condition. A larger sample, subdivided by disease severity and 495
medication class as well as type, will be able to clarify this matter 496
further. 497
From a theoretical perspective, the ﬁnding that dopaminer- 498
gic medication leads to a selective decline in recollection and 499
with relatively greater sparing of familiarity is consistent with 500
the view that these component recognition memory processes are 501
supported by separate neural networks. The Aggleton and Brown 502
(1999, 2006) model assigns the perirhinal cortex and its projec- 503
tion site, the mediodorsal thalamus, a speciﬁc role in the mediation 504
of familiarity during recognition. This network is distinct from an 505
extended hippocampal system involving the fornix, mammillary 506
bodies, mammillothalamic tract, and anterior thalamus that sup- 507
ports free recall and the recollection of episodic details during 508
recognition. According to this model, damage to the hippocam- 509
pus in the presence of relative sparing of the perirhinal cortex 510
should bemarked by a selective impairment in the recollection and 511
preservation of familiarity. This pattern of impairment is present 512
in our moderate Parkinson’s group when tested both ON- and OFF- 513
medication. 514
The robustness of our reported dissociation between spared 515
familiarity and deﬁcient recollection in the moderate Parkinson’s 516
group has a striking similarity to the reports of patients with selec- 517
tive lesions of the hippocampus (e.g., Aggleton et al., 2005; Bastin et 518
al., 2004; Mayes, Holdstock, Isaac, Hunkin, & Roberts, 2002; Mayes 519
et al., 2004; Vargha-Khademet al., 1997; Yonelinas et al., 2002) and 520
fornix (Tsivilis et al., 2008; Vann et al., 2009) who are able to per- 521
form normally on familiarity/recognition in the face of impaired 522
recollection/recall tasks; and functional brain imaging reports of 523
healthy volunteers showing the hippocampus is critical to the 524
recollection of episodic detail during recognition (e.g., Montaldi, 525
Spencer, Roberts, & Mayes, 2006). Furthermore, the presence of 526
other groups of lesion patients with damage to the perirhinal cor- 527
tex (Bowles et al., 2007;Haskins, Yonelinas, Quamme,&Ranganath, 528
2008; see reviews by Eichenbaum, Yonelinas, & Ranganath, 2007; 529
Mayes, Montaldi, & Migo, 2007) that spares the hippocampus 530
indicates that familiarity/recognition and recollection/recall can 531
doubly dissociate in patient groups with different medial temporal 532
lobe and diencephalic pathology. 533
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In sum, the results of the current study demonstrate that534
nondementingmoderateParkinson’s canselectively impair the rec-535
ollection of episodic details during recognition. Together with past536
ﬁndings showing that hippocampal lesions can result in a dissoci-537
ation between (deﬁcient) recollection and (preserved) familiarity,538
our study provides further support for a dual- rather than single539
dimension account in which recollection and familiarity are sep-540
arate processes that are combined into a single dimension (see541
Dunn, 2004; Wixted, 2007; Wixted & Stretch, 2004; for arguments542
supporting a single dimension account). Our results also raise the543
possibility that this recollection deﬁcit may be exacerbated by rou-544
tine dopaminergic medication used to control motor symptoms545
in Parkinson’s. This ﬁnding argues against the l-dopa overdose546
hypothesis and raises the possibility that overactivation or abnor-547
mal stimulation of postsynaptic dopamine receptors by second548
generationnonergolinedopamineagonistsmayplay a contributory549
role.550
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